Y
Ya-Ting Chang
Researcher at Kaohsiung Medical University
Publications - 13
Citations - 798
Ya-Ting Chang is an academic researcher from Kaohsiung Medical University. The author has contributed to research in topics: Stenotrophomonas maltophilia & Carbapenem. The author has an hindex of 10, co-authored 13 publications receiving 520 citations. Previous affiliations of Ya-Ting Chang include National Cheng Kung University.
Papers
More filters
Journal ArticleDOI
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
TL;DR: A synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents is provided.
Journal ArticleDOI
Infections Caused by Carbapenem-Resistant Enterobacteriaceae : An Update on Therapeutic Options.
TL;DR: The current understanding of issues related to CRE is described and combination therapeutic strategies for CRE infections, including high-dose tigecycline, high- dose prolonged-infusion of carbapenem, and double carbapENem therapy are reviewed.
Journal ArticleDOI
Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections.
Ya-Ting Chang,Chun-Yu Lin,Po-Liang Lu,Chung-Chih Lai,Tun-Chieh Chen,Chi-Yu Chen,Deng-Chyang Wu,Tzu-Pin Wang,Chiu-Mei Lin,Chiu-Mei Lin,Wei-Ru Lin,Yen-Hsu Chen +11 more
TL;DR: Characteristics of patients with community-onset S. maltophilia bloodstream infection have reduced disease severity and lower mortality rate when compared to hospital-acquired SMBSI, and underlying structural/mechanical abnormalities, especially those caused by malignancies, are common inSMBSI cases and should be investigated when bacteremia occurs.
Journal ArticleDOI
Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010–2013
Ya-Ting Chang,Geoffrey W. Coombs,Thomas K. W. Ling,V. Balaji,Camilla Rodrigues,Hiroshige Mikamo,Min Ja Kim,Datin Ganeswrie Rajasekaram,Myrna Mendoza,Thean Yen Tan,Pattarachai Kiratisin,Yuxing Ni,Weinman Barry,Yingchun Xu,Yen-Hsu Chen,Yen-Hsu Chen,Po-Ren Hsueh +16 more
TL;DR: Investigation of the epidemiology and antimicrobial susceptibility patterns of Gram-negative bacilli isolated from intra-abdominal infections in the Asia-Pacific region from 2010-2013 found high in vitro activity against all GNB isolates causing IAIs, except for Acinetobacter calcoaceticus-baumannii (ACB) complex.
Journal ArticleDOI
Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
TL;DR: Recently, ceftolozane/tazobactam and ceftazidime/avibactam have been approved for the treatment of complicated urinary tract infections and complicated intra-abdominal infections and the introduction of these new β-lactam/β- lactamase inhibitor combinations offers new carbapenem-sparing options for the Treatment of ESBL infections.